Hugel (145020) Q2 2026 earnings summary

Executive summary

• Global medical aesthetics company specializing in botulinum toxin (Botulax), HA fillers, cosmetics, threads, and skin boosters, with a strong international presence and diversified product portfolio.

• Revenue for the half-year ended June 30, 2026, was KRW 254.5 billion, with 57.8% from toxin products and 25.9% from fillers/skin boosters.

• Major shareholder is Aphrodite Acquisition Holdings LLC, holding 43.53% of shares.

Financial highlights

• Consolidated revenue for H1 2026: KRW 254.5 billion, down from KRW 425.1 billion in 2025 and KRW 373.0 billion in 2024.

• Operating income for H1 2026: KRW 103.7 billion; net income: KRW 85.3 billion.

• Gross margin for H1 2026: KRW 195.8 billion; operating margin remains robust.

• Cash and cash equivalents at June 30, 2026: KRW 259.6 billion.

• Earnings per share (EPS) for H1 2026: KRW 7,645 (basic).

Outlook and guidance

• Continued focus on expanding global market share, especially in the US, Europe, and China.

• New product launches and regulatory approvals in multiple countries expected to drive future growth.

• Ongoing investment in R&D and product pipeline, including next-generation botulinum toxin and skin booster products.